DeepMed Research

Iohexol

Generic Name: Iohexol

Brand Names: Omnipaque, Oraltag

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₆I_₃N_₃O_₉

CAS Number: 66108-95-0

Unique Ingredient Identifier: 4419T9MX03

Background: Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Indication: Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

Clinical Trials

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

Phase 1

Completed

Conditions: Drug-drug Interaction

Interventions: Drug: Tucatinib
Drug: Metformin
Drug: Iohexol

First Posted Date: 2019-02-01

Last Posted Date: 2019-03-27

Lead Sponsor: Seagen Inc.

Target Recruit Count: 18

Registration Number: NCT03826602

Locations: 🇺🇸
Pharmaceutical Research Associates, Salt Lake City, Utah, United States

Description of the Evolution of Plasma and Urinary Concentrations of Iohexol in a Cirrhotic Patient Population

Phase 4

Completed

Conditions: Cirrhosis Renal

Interventions: Drug: Iohexol Inj 300 MG/ML

First Posted Date: 2018-12-07

Last Posted Date: 2019-09-25

Lead Sponsor: University Hospital, Limoges

Target Recruit Count: 13

Registration Number: NCT03769597

Locations: 🇫🇷
University Hospital, Limoges, France

Effect of Evolocumab on Coronary Atherosclerosis

Phase 3

Completed

Conditions: Cardiovascular Disease
Hyperlipidemia

Interventions: Drug: Evolocumab
Diagnostic Test: 18F-NaF PET
Diagnostic Test: CCTA
Drug: Omnipaque
Drug: Metoprolol
Drug: Nitroglycerin

First Posted Date: 2018-10-01

Last Posted Date: 2024-07-17

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 55

Registration Number: NCT03689946

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Phase 4

Withdrawn

Conditions: Hypothyroidism

Interventions: Drug: Iohexol
Drug: Iodixanol
Drug: Iopromide
Drug: Ioversol

First Posted Date: 2018-08-15

Last Posted Date: 2022-04-20

Lead Sponsor: GE Healthcare

Registration Number: NCT03631771

Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes

Phase 1

Active, not recruiting

Conditions: Diabetes Complications
Weight Loss
Diabetic Nephropathies
Type 2 Diabetes Mellitus
Obesity
Bariatric Surgery Candidate
Nephropathy
Diabetic Kidney Disease
Diabetes Mellitus, Type 2
Diabetes Mellitus

Interventions: Drug: Aminohippurate Sodium Inj 20%
Drug: Iohexol Inj 300 mg/mL
Procedure: Vertical Sleeve Gastrectomy
Procedure: Renal Biopsy

First Posted Date: 2018-08-08

Last Posted Date: 2024-04-05

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 30

Registration Number: NCT03620773

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

Phase 1

Completed

Conditions: Diabetic Nephropathies
Diabetes Mellitus Complication
Autoimmune Diabetes
Juvenile Diabetes
Diabetes Mellitus, Type 1
Nephropathy
Type 1 Diabetes Mellitus

Interventions: Drug: Aminohippurate Sodium Inj 20%
Drug: Iohexol Inj 300 mg/mL

First Posted Date: 2018-08-07

Last Posted Date: 2022-04-20

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 50

Registration Number: NCT03618420

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

Phase 1

Active, not recruiting

Conditions: Adolescent Obesity
Type 2 Diabetes Mellitus
Obesity
Nephropathy

Interventions: Drug: Aminohippurate Sodium Inj 20%
Drug: Iohexol Inj 300 MG/ML
Procedure: Renal Biopsy

First Posted Date: 2018-07-12

Last Posted Date: 2023-08-15

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 100

Registration Number: NCT03584217

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

Phase 1

Withdrawn

Conditions: Renal Insufficiency

Interventions: Drug: Lanabecestat
Drug: Iohexol

First Posted Date: 2018-06-04

Last Posted Date: 2018-06-28

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT03545087

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Ctr., Orlando, Florida, United States

Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight

Phase 4

Completed

Conditions: Contrast Media Dosing

Interventions: Drug: Iohexol

First Posted Date: 2018-01-30

Last Posted Date: 2019-01-31

Lead Sponsor: Nova Scotia Health Authority

Target Recruit Count: 239

Registration Number: NCT03415997

Locations: 🇨🇦
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure

Phase 3

Conditions: Acute Renal Failure

Interventions: Drug: IOHEXOL

First Posted Date: 2016-11-11

Last Posted Date: 2019-03-19

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 150

Registration Number: NCT02961478

Locations: 🇫🇷
University Hospital, Tours, France
🇫🇷
Hospital center, Chartres, France
🇫🇷
Hospital, Le Mans, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy